2023 ASCO中国之声｜乳腺癌领域壁报部分共25项中国研究入选！

一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，致力于癌症的预防、治疗和改善患者管理，以展示肿瘤的基础研究和临床最新研究为特点，讨论当前国际先进的治疗方法。随着中国临床研究在肿瘤领域的快速成长，中国在世界肿瘤领域中也发挥着日益重要的作用。此次会议上，中国乳腺癌领域Poster Session共入选25项。期待中国专家在ASCO年会上展现风采！

标题：Differences of prediction performances by multigene assays in patients with breast cancer with distinct genetic backgrounds.

报告人：邢飞

单位：中国医科大学附属盛京医院

标题：Differential benefit of capecitabine-based chemotherapy among TNBC subtypes in the context of the CBCSG010 study.

报告人：李俊杰

单位：复旦大学附属肿瘤医院

标题：Cardiac safety and efficacy for patients with early-stage breast cancer treated with pegylated liposomal doxorubicin (PLD) or doxorubicin.

报告人：Lichen Tang, M.D.

单位：复旦大学附属肿瘤医院

标题：Trends and outcomes of systemic therapy in hormone receptor-positive early-stage male breast cancer: A propensity score analysis.

报告人：Liuwen Yu, M.M

单位：福建医科大学附属协和医院

标题：Decision value of the circulating tumor DNA on the adjuvant anti-Her2 regimens in patients with Her2-positive breast cancer treated with neoadjuvant therapy.

报告人：Po-Han Lin, MD

单位：国立台湾大学医院

标题：ERBB2 mRNA expression to distinguish HER2-low/neg breast cancer prognosis.

报告人：刘月平

单位：河北医科大学第四医院

标题：Taxane combined with lobaplatin or anthracycline for neoadjuvant treatment of triple-negative breast cancer: A single-center, randomized, controlled, phase-II clinical study.

报告人：Cheng Wang

单位：陆军军医大学西南医院

标题：Use of PLR and NLR to evaluate the efficacy and prognosis of neoadjuvant chemotherapy with lobaplatin in triple-negative breast cancer.

报告人：Cheng Wang

单位：陆军军医大学西南医院

标题：Longitudinal MRI-based fusion novel model to predict pathological complete response in breast cancer treated with neoadjuvant chemotherapy: A multicenter, retrospective study.

报告人：王坤

单位：广东省人民医院肿瘤医院

标题：Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin followed by adjuvant tislelizumab in patients with early triple-negative breast cancer.

报告人：江泽飞

单位：解放军总医院第五医学中心

标题：A prospective, phase II, neoadjuvant clinical study based on chemotherapy sensitivity in hormone receptor–positive, HER2-negative breast cancer: FINEST study.

报告人：陈力

单位：复旦大学附属肿瘤医院

标题：ORACLE-RIPA study: A phase II, randomized, open-label, parallel-group study comparing the immune modulation effect of neoadjuvant ribociclib, palbociclib, and abemaciclib in early ER+/HER2- breast cancer.

报告人：I-Chun Chen, MD, PhD

单位：国立台湾大学医院

标题：Clinical features, genomic landscapes, and survival outcomes of HER2-low breast cancer.

报告人：Jin Juan

单位：复旦大学附属肿瘤医院

标题：Negative estrogen receptor expression assessed by 18F-FES PET in metastatic breast cancer with ER-positive primary tumor.

报告人：王碧芸

单位：复旦大学附属肿瘤医院

标题：Preclinical and early clinical data of ZN-1041, a best-in-class BBB penetrable HER2 inhibitor to treat breast cancer with CNS metastases.

报告人：马飞

单位：中国医学科学院肿瘤医院

标题：Anti-HER2 antibody inetetamab plus camrelizumab and utidelone for pretreated HER2-positive metastatic breast cancer: Final results from the phase 2 ICU trial.

报告人：律慧敏

单位：河南省肿瘤医院

标题：Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): Updated results from a phase 1b/2 study.

报告人：王晓稼

单位：中国科学院大学附属肿瘤医院（浙江省肿瘤医院）

标题：Updated results from a phase 2 study on dalpiciclib and pyrotinib, a dual-oral chemotherapy-free regimen in HER2-positive advanced breast cancer (DAP-HER-01).

报告人：闫敏

单位：河南省肿瘤医院

标题：PLEASURABLE: Results and biomarkers analysis from the phase II study of dalpiciclib combined with pyrotinib and endocrine therapy (ET) in women with dual-receptor positive (ER+/HER2+) metastatic breast cancer (MBC).

报告人：张剑

单位：复旦大学附属肿瘤医院

标题：Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases: 3-year follow-up results from the phase 2 PERMEATE trial.

报告人：闫敏

单位：河南省肿瘤医院

标题：A multicenter, single-arm, open-label trial of birociclib, a CDK4/6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer.

报告人：王佳玉

单位：中国医学科学院肿瘤医院

标题：Influence of chromatin remodeling molecule ARID1A on metastatic heterogeneity in triple negative breast cancer: Binding of YAP.

报告人：Ye Wang

单位：复旦大学附属肿瘤医院

标题：The overall survival analysis of FUTURE-C-PLUS: Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for advanced, immunomodulatory triple-negative breast cancer—An open-label, single-arm, phase 2 trial.

报告人：陈力

单位：复旦大学附属肿瘤医院

标题：ARID1A deficiency in triple-negative breast cancer induces adaptive immune resistance and sensitivity to immune checkpoint inhibitors.

报告人：Margaret Chen

单位：复旦大学附属肿瘤医院

标题：Preliminary results from a first-in-human study of ESG401, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients with locally advanced/metastatic solid tumors.

报告人：马飞

单位：中国医学科学院肿瘤医院